Australian prescribers' perspectives on ART initiation in the era of “treatment as prevention”
- 13 February 2013
- journal article
- research article
- Published by Taylor & Francis in AIDS Care
- Vol. 25 (11) , 1375-1379
Abstract
This study explores Australian prescribers' attitudes towards Treatment as Prevention (TasP) and their practices around initiating combination antiretroviral treatment (cART) for HIV. A brief online survey was conducted nationally amongst antiretroviral treatment (ART) prescribers in Australia. The sample broadly represented ART prescribers in Australia (N = 108), with 40.7% general practitioners (GPs), 25.9% sexual health clinic-based physicians and 21.3% hospital-based infectious diseases physicians. About 60% of respondents had been treating HIV-positive patients for more than 10 years. Respondents estimated that about 70–80% of all their HIV-positive patients were receiving ART. Over half of the prescribers agreed very strongly that their primary concern in recommending cART initiation was clinical benefit to individual patients rather than any population benefit. A majority of the prescribers (68.5%) strongly endorsed cART initiation before CD4+ T-cell count drops below 350 cells/mm3, and a further 22.2% strongly endorsed cART initiation before CD4+ T-cell count drops below 500 cells/mm3. Regarding the optimal timing of cART initiation, this study shows that prescribers in Australia in 2012 focus primarily on the benefits for their individual patients. Prescribers may need more convincing evidence of individual health benefits or increased knowledge about the population health benefits for a TasP approach to be effective in Australia.Keywords
This publication has 20 references indexed in Scilit:
- Projected Demographic Profile of People Living with HIV in Australia: Planning for an Older GenerationPLOS ONE, 2012
- HIV Treatment as Prevention: Natural Experiments Highlight Limits of Antiretroviral Treatment as HIV PreventionPLOS Medicine, 2012
- Adherence to HIV Treatment Guidelines for Comorbid Disease Assessment and Initiation of Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Behavioral Factors in Assessing Impact of HIV Treatment as PreventionAIDS and Behavior, 2012
- Prevention of HIV-1 Infection with Early Antiretroviral TherapyNew England Journal of Medicine, 2011
- Trends in detectable viral load by calendar year in the Australian HIV observational databaseJournal of the International AIDS Society, 2011
- Data are lacking for quantifying HIV transmission risk in the presence of effective antiretroviral therapyAIDS, 2009
- Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical modelThe Lancet, 2009
- HIV transmission under highly active antiretroviral therapyThe Lancet, 2008
- Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART StudyThe Journal of Infectious Diseases, 2008